Enfusion (NYSE:ENFN – Get Free Report) and AvePoint (NASDAQ:AVPT – Get Free Report) are both computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.
Profitability
This table compares Enfusion and AvePoint’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enfusion | 1.98% | 6.17% | 4.51% |
| AvePoint | -4.77% | -6.66% | -3.32% |
Analyst Recommendations
This is a summary of recent ratings for Enfusion and AvePoint, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enfusion | 3 | 2 | 1 | 0 | 1.67 |
| AvePoint | 0 | 1 | 3 | 0 | 2.75 |
Earnings & Valuation
This table compares Enfusion and AvePoint”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enfusion | $188.35 million | 5.50 | $6.03 million | $0.03 | 269.33 |
| AvePoint | $299.88 million | 7.28 | -$21.50 million | ($0.08) | -147.38 |
Enfusion has higher earnings, but lower revenue than AvePoint. AvePoint is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
81.1% of Enfusion shares are owned by institutional investors. Comparatively, 44.5% of AvePoint shares are owned by institutional investors. 36.4% of Enfusion shares are owned by company insiders. Comparatively, 27.8% of AvePoint shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Enfusion has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, AvePoint has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.
Summary
Enfusion beats AvePoint on 10 of the 14 factors compared between the two stocks.
About Enfusion
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.
About AvePoint
AvePoint, Inc. provides cloud-native data management software platform in North America, Europe, Middle East, Africa, and Asia Pacific. It also offers software-as-a-service solutions and productivity applications. The company offers modularity and cloud services architecture to address critical challenges and the management of data to organizations that leverage third-party cloud vendors, including Microsoft, Salesforce, Google, AWS, Box, DropBox, and others; license and support; and maintenance services. AvePoint, Inc. was incorporated in 2001 and is headquartered in Jersey City, New Jersey.
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.
